Dr. Michael Kyle explains how Contrave supports personalized obesity treatment, reduces cravings, and aids long-term weight management.

Dr. Michael Kyle discusses the complexity of obesity and the need for tailored treatment approaches. He explains how Contrave, a combination of bupropion and naltrexone, works in the brain to reduce appetite and control cravings, supporting patients in following nutrition and lifestyle plans. He also shares insights on long-term weight management, medication safety, and patient-provider collaboration.

Dr. Michael Kyle is the Chief Medical Officer at Currax Pharmaceuticals with a background spanning medical practice and clinical research. He is dedicated to helping people live longer, healthier lives through evidence-based obesity treatment and education. Dr. Kyle works to increase understanding of obesity as a chronic disease, promote personalized care, and expand global access to safe and effective medications like Contrave.

LinkedIn: https://www.linkedin.com/in/michael-l-kyle/